Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics

Marketwired December 18, 2014

New AUGMENT(SM) Fertility Treatment Now Available in Canada

Canada NewsWire December 18, 2014

Claritas Genomics Appoints Patrick F. Terry as Chief Commercial Officer

PR Newswire December 18, 2014

New data presented at American Society of Hematology (ASH) shows specific antidote idarucizumab* reverses dabigatran-induced anticoagulation independent of age, and kidney function

Canada NewsWire December 18, 2014

Strategic Science and Technologies Signs Partnership Agreement with a Leading Global Pharmaceutical Company for U.S. Commercial Rights to Topical Ibuprofen

Business Wire December 18, 2014

Appistry Announces New Fellowship in Life Science Informatics and Entrepreneurship

Business Wire December 18, 2014

Dyax Corp.'s First-in-Human Trial for DX-2930 Conducted by Vince and Associates Clinical Research Featured in the Annals of Allergy, Asthma & Immunology

Business Wire December 18, 2014

Alnylam Elects Michael W. Bonney to Its Board of Directors

Business Wire December 18, 2014

Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform

Business Wire December 18, 2014

Research and Markets: Russia Wound Debridement Devices Market Outlook to 2020: Key Players Covered Include Smith & Nephew, Zimmer Holdings and Soring

Business Wire December 18, 2014

Research and Markets: South Korea Digital Wound Measurement Devices Market Outlook to 2020

Business Wire December 18, 2014

Raptor Pharmaceutical Appoints Gregg Lapointe and Georges Gemayel to Board of Directors

GlobeNewswire December 18, 2014

Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers

Business Wire December 18, 2014

Padlock Therapeutics Secures $23 Million Series A Financing Led by Atlas Venture

Business Wire December 18, 2014

Research and Markets: South Korea Capsule Endoscopy Systems Market Outlook to 2020: Key Players Covered Include Given Imaging and Olympus Corporation

Business Wire December 18, 2014

BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema

GlobeNewswire December 18, 2014

Compugen Enters Immuno-Oncology Research Collaboration with Johns Hopkins University

Business Wire December 18, 2014

Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study

GlobeNewswire December 18, 2014

Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors

GlobeNewswire December 18, 2014

Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant

GlobeNewswire December 18, 2014